Cassava Sciences, Inc. (SAVA) financial statements (2020 and earlier)

Company profile

Business Address 7801 N CAPITAL OF TEXAS HIGHWAY
AUSTIN, TX 78731
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:23201019314150
Cash and cash equivalents23201017314149
Short-term investments   2  1
Other undisclosed cash, cash equivalents, and short-term investments     (0)(0)
Other current assets0000000
Other undisclosed current assets     00
Total current assets:23201119324150
Noncurrent Assets
Property, plant and equipment000000 
Other noncurrent assets 00 00 
Other undisclosed noncurrent assets0      
Total noncurrent assets:000000 
TOTAL ASSETS:23201119324150
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111311
Accounts payable0000100
Accrued liabilities10001  
Employee-related liabilities0000111
Other liabilities0      
Other undisclosed current liabilities0    01
Total current liabilities:1111312
Noncurrent Liabilities
Total liabilities:1111312
Stockholders' equity
Stockholders' equity attributable to parent22201019294048
Common stock0000000
Additional paid in capital191184167164160157152
Accumulated other comprehensive income     00
Accumulated deficit(169)(164)(157)(145)(131)(116)(104)
Total stockholders' equity:22201019294048
TOTAL LIABILITIES AND EQUITY:23201119324150

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:      41
Operating expenses(5)(7)(12)(15)(14)(12)(10)
Operating income (loss):(5)(7)(12)(15)(14)(12)31
Income (loss) from continuing operations before equity method investments, income taxes:(5)(7)(12)(15)(14)(12)31
Other undisclosed income from continuing operations before income taxes    000
Income (loss) from continuing operations before income taxes:(5)(7)(12)(15)(14)(12)31
Income tax benefit      0
Net income (loss):(5)(7)(12)(15)(14)(12)32
Other undisclosed net income attributable to parent0000   
Net income (loss) available to common stockholders, diluted:(5)(7)(12)(15)(14)(12)32

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(5)(7)(12)(15)(14)(12)32
Other comprehensive loss    (0) (0)
Comprehensive income (loss):(5)(7)(12)(15)(14)(12)32
Other undisclosed comprehensive income, net of tax, attributable to parent  00   
Comprehensive income (loss), net of tax, attributable to parent:(5)(7)(12)(15)(14)(12)32

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: